New BD Assay Speeds Discovery in Autoimmune Disorders, Immuno-Oncology, and Infectious Diseases

The BD Rhapsody TCR/BCR Multiomic Assay supplies immunology researchers the specific reagents required to profile full-length T cell and B cell receptors, two of the most important cellular elements in the immune system, to better understand the adaptive immune response and enable applications such as evaluating cellular responses to new drugs. The BD Rhapsody TCR/BCR Multiomic Assay has a wide range of applications, including screening for antigen specific cells in response to infectious diseases, immune repertoire profiling of tumor infiltrating lymphocytes, and vaccine development and evaluation of efficacy. The assay is optimized to work with the company’s BD Rhapsody Single-Cell Analysis System workflow, which enables higher capture rates than currently available solutions, preserving fragile cells in the process. This first-generation kit is now available globally and is the latest addition to BD’s portfolio of tools for multiomic analysis.

“With the release of the BD Rhapsody TCR/BCR Multiomic Assay, we are reinforcing our commitment to the incredibly exciting field of multiomics and single-cell research and the delivery of robust, easy-to-use tools that offer researchers valuable and deep insights,” said Puneet Sarin, worldwide president at BD Biosciences. “Single-cell analysis tools like the BD Rhapsody TCR/BCR Multiomic Assay and BD Rhapsody Single-Cell Analysis System support our customers’ need for greater sensitivity and specificity studying cells of interest and drive rapid advancements in immunology, including research in therapeutic response and cell therapy.”

Related Links:
Becton, Dickinson and Company